Tethis Collaborates with Sheba to Transform Rectal Cancer Detection
Tethis Partners with Sheba Medical Center for Innovative Research
In an exciting development in the medical field, Tethis S.p.A. and Sheba Medical Center have announced a groundbreaking research collaboration aimed at enhancing the management of rectal cancer using advanced AI-powered liquid biopsy techniques. At the heart of this collaboration is the installation of Tethis' proprietary See.d instrument at Sheba's Institute of Pathology, designed to evaluate circulating tumor cells (CTCs) in patients diagnosed with rectal cancer.
Understanding the Study's Goals
The research, guided by the expertise of Professor Iris Barshack, focuses on the monitoring of CTCs and circulating tumor DNA (ctDNA) in rectal cancer patients throughout their treatment journey. This innovative approach involves collecting blood samples at different intervals to assess baseline CTC levels, enabling researchers to track changes over time. With this methodology, the team hopes to establish CTCs and ctDNA as reliable surrogate markers for predicting cancer relapse sooner than traditional imaging methods.
The Technology Behind the Collaboration
Dr. Holger Neecke, CEO of Tethis, has expressed enthusiasm about this partnership: "Working with Sheba represents a significant step in expanding the applications of our liquid biopsy platform. Our See.d instrument, coupled with our specialized SmartBioSurface slides, allows for the standardized preparation of cytology specimens. This is essential for collecting critical data regarding both immune and tumor cells, ultimately supporting enhanced analysis with AI technologies.
Advancing Precision Medicine
Sheba Medical Center is renowned for its innovative approach to healthcare. Prof. Iris Barshack highlighted the collaboration's importance, stating, "This partnership exemplifies Sheba's commitment to enhancing precision medicine through cutting-edge technologies. By leveraging Tethis' advancements in liquid biopsy, we aim to create more effective treatment response monitoring strategies for rectal cancer patients.
Innovations in Cytology Analysis
Dr. Nadia Prisant, who leads the Liquid Biopsy Laboratory, emphasized the impact of this collaboration on the field of digital cytology: "By utilizing bright field multi-staining immunohistochemistry combined with AI algorithms, we are building upon previous successful studies. The ability to prepare high-quality cytology slides at the time of blood collection is invaluable in understanding disease progression, thereby guiding treatment decisions.
Implications for Early Detection
Prof. Ruth Katz, a prominent figure in pathology, added to the conversation by discussing the method's potential: "With the See.d instrument, we can obtain a comprehensive population of nucleated cells, including crucial CTCs and inflammatory cells, from the bloodstream. This gentle collection technique enhances our capacity to identify CTC clusters and individual cells, which are vital in developing treatment plans, particularly in early-stage patients.
Commitment to Research Purposes
It is important to note that the See.d instrument and SmartBioSurface slides are designated for Research Use Only. Their application is not intended for diagnostic procedures, ensuring that the journey undertaken by Tethis and Sheba remains focused on innovative research and experimental development.
About Tethis
Tethis is at the forefront of developing technologies that integrate liquid biopsy within clinical landscapes, enhancing cancer management protocols. The company is dedicated to standardizing blood sample preparation to maintain unparalleled quality and integrity in liquid biopsy specimens. By facilitating thorough analysis of clinically relevant biomarkers, Tethis is pioneering methods that enable the accurate identification of rare cells, such as circulating tumor cells. The firm operates from its headquarters in Milan, Italy.
About Sheba Medical Center
As the largest medical center in the region, Sheba Medical Center is reshaping healthcare globally through its innovative treatments and research initiatives. The center boasts various specialized departments, including acute care, rehabilitation, and oncology, fostering a culture of excellence that transcends borders. Sheba prioritizes welcoming international patients and healthcare professionals, continuously delivering top-tier medical care.
Frequently Asked Questions
What is the purpose of the collaboration between Tethis and Sheba Medical Center?
The collaboration aims to advance the use of AI-powered liquid biopsy technology in monitoring rectal cancer patients and improving treatment strategies.
What technology is being utilized in this research?
The research utilizes Tethis' See.d instrument and SmartBioSurface slides for analyzing circulating tumor cells and ctDNA in blood samples.
Who is leading the study at Sheba Medical Center?
The study is being led by Professor Iris Barshack from the Institute of Pathology at Sheba Medical Center.
What is the expected outcome of this study?
The study aims to establish liquid biopsy markers that can predict cancer relapse earlier than traditional imaging techniques.
Is Tethis’ technology available for diagnostic use?
No, the See.d instrument and SmartBioSurface slides are intended for research purposes only and not for diagnostic applications.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
